MEDSCHOLARS - Key Persons
Endocrinologist Aaron Hsueh discovers obestatin, a hormone that supresses appetite and may lead to treatments for obesity.
Job Titles:
- Named Chair of Dept. of Neurology & Neurological Sciences
I am delighted to share that Antonio Omuro, MD, Professor of Neurology at the Yale University School of Medicine, has been appointed chair of the Department of Neurology and Neurological Sciences. Dr. Omuro currently holds leadership roles spanning the Yale-New Haven Health Care System and the Yale School of Medicine, including as chief of Neuro-Oncology at Yale Cancer Center and founding director of the Yale Family Brain Tumor Center. He will begin his new role at Stanford on February 1, 2024.
Dr. Omuro is regarded as one of the foremost physician-scientists studying brain tumors. A fellow of the American Academy of Neurology, he has published more than 140 peer-reviewed research articles and led dozens of clinical trials focused on developing new treatments for brain tumors and neurologic complications of cancer. Recently, he led the development of immune-checkpoint inhibitors for glioblastoma from the first Phase 1 studies through the largest Phase 3 international clinical trial ever conducted in this disease.
Dr. Omuro also has a long track record of visionary leadership that has helped elevate Yale's neuro-oncology division to one of the strongest in its field while increasing patient visits to Yale Cancer Center by 74 percent. While at Yale, Dr. Omuro has fostered a culture of academic excellence, attracted and retained world-class faculty and research staff, led teams of clinicians and basic scientists in collaborative grants and projects, and embedded clinical trials throughout its practice. Critically, he also has championed diversity, equity, and inclusion by actively supporting Yale Cancer Center's Diversity, Equity, and Inclusion Council.
Beyond research and clinical care, Dr. Omuro has made significant strides in cultivating the next generation neurology and neurological sciences leaders. For more than two decades, he has served as a highly respected teacher and mentor of students, residents, and fellows, particularly to women and those from underrepresented groups. Many are now highly influential in the field. Nationally, he has advised the American Academy of Neurology as a member of its Science Committee to design innovative educational activities and shape scientific standards for research conduct.
I want to express my deep appreciation to our search committee - co-led by Tina Stankovic, MD, PhD, and Michael Lim, MD - for conducting a comprehensive national search to fill this critical position. Both David Entwistle, president and CEO of Stanford Health Care, and Paul King, president and CEO of Stanford Medicine Children's Health, share my strong support of Dr. Omuro's appointment.
I also want to thank the interim chair of the Department of Neurology and Neurological Sciences, Paul Fisher, MD. Dr. Fisher seamlessly stepped into this role on July 1 and has provided stability and strong leadership at a time of transition. I have the utmost confidence that he will continue to effectively bridge this transition.
Pharmacologist Avram Goldstein discovers a chemical in the human brain that could lead to the development of powerful painkillers with fewer undesirable side effects.
Job Titles:
- Assistant Director, Medical Student Research & Scholarship
Job Titles:
- PRESIDENT & CEO / STANFORD HEALTH CARE
Job Titles:
- Dean
- Head
- Physician
- Scientist
- Surgeon
- DEAN, STANFORD SCHOOL of MEDICINE
- Professor for the Dean
- Vice Dean Linda M. Boxer
Dean Minor is a leading physician, basic scientist and educator.
Lloyd B. Minor, MD, is a scientist, surgeon, and academic leader. He is the Carl and Elizabeth Naumann Dean of the Stanford University School of Medicine, a position he has held since December 2012. He also is a professor of Otolaryngology-Head and Neck Surgery and a professor of Bioengineering and of Neurobiology, by courtesy, at Stanford University.
As dean, Dr. Minor plays an integral role in setting strategy for the clinical enterprise of Stanford Medicine, an academic medical center that includes the Stanford University School of Medicine, Stanford Health Care, and Stanford Medicine Children's Health. With his leadership, Stanford Medicine leads the biomedical revolution in Precision Health. His book, "Discovering Precision Health," describes this shift to more preventive, personalized health care and highlights how biomedical advances are dramatically improving our ability to treat and cure complex diseases. In 2021, Dr. Minor articulated and began realizing a bold vision to transform the future of life sciences at Stanford University and beyond - a multi-decade journey enabled by Precision Health.
Before Stanford, Dr. Minor was provost and senior vice president for academic affairs of Johns Hopkins University. Prior to this appointment in 2009, Dr. Minor served as the Andelot Professor and director (chair) of the Department of Otolaryngology-Head and Neck Surgery in the Johns Hopkins University School of Medicine and otolaryngologist-in-chief of The Johns Hopkins Hospital.
With more than 160 published articles and chapters, Dr. Minor is an expert in balance and inner ear disorders perhaps best known for discovering superior canal dehiscence syndrome, a debilitating disorder characterized by sound- or pressure-induced dizziness. He subsequently developed a surgical procedure that corrects the problem and alleviates symptoms.
In 2012, Dr. Minor was elected to the National Academy of Medicine.
Carl and Elizabeth Naumann Professor for the Dean of the School of Medicine, Professor of Otolaryngology - Head & Neck Surgery, and by courtesy, of Neurobiology & Bioengineering
As part of the Stanford Executive Briefing series, Minor shares his thoughts on authentic leadership and offers five leadership principles.
Lloyd B. Minor, MD, is a scientist, surgeon, and academic leader. He is the Carl and Elizabeth Naumann Dean of the Stanford University School of Medicine, a position he has held since December 2012. He also is a professor of Otolaryngology-Head and Neck Surgery and a professor of Bioengineering and of Neurobiology, by courtesy, at Stanford University.
As dean, Dr. Minor plays an integral role in setting strategy for the clinical enterprise of Stanford Medicine, an academic medical center that includes the Stanford University School of Medicine, Stanford Health Care, and Stanford Medicine Children's Health. He oversees the quality of Stanford Medicine's physicians on the faculty and in the growing clinical networks and physician practices.
At the beginning of the COVID-19 pandemic, Dr. Minor reacted quickly to implement protocols to ensure the safety of patients and of the Stanford Medicine community. He emphasized open communication, transparency, and accountability as he and the leadership team responded to the unprecedented challenges that affected every facet of the enterprise's activities.
With Dr. Minor's leadership, Stanford Medicine is leading the biomedical revolution through Precision Health. Empowering people to lead healthy lives, Precision Health is a fundamental shift to more proactive and personalized health care that predicts and prevents disease before it strikes and cures it decisively if it does. His book, "Discovering Precision Health: Predict, Prevent, and Cure to Advance Health and Well-Being," highlights how biomedical advances are dramatically improving our ability to treat and cure complex diseases.
Dr. Minor also spearheaded the creation of an Integrated Strategic Plan (ISP) that reaffirms Stanford Medicine's Precision Health vision while articulating a new commitment to be Human Centered and Discovery Led. An unprecedented roadmap, the ISP aligns Stanford Medicine's three entities, informs how each will develop strategies and make decisions, and is activating more than two dozen high-impact initiatives across Stanford Medicine.
In 2021, Dr. Minor articulated and began realizing a bold vision for transforming the future of life sciences at Stanford University, in the Bay Area, and beyond. This multi-decade journey will leverage the region's unique strengths in information sciences, technology, and biology and biomedicine to establish a biomedical innovation hub that through collaboration enhances fundamental understanding of biology and translates promising discoveries into transformative leaps that promote human and planetary well-being.
Dr. Minor has long provided significant support for basic science research and for clinical and translational research at Stanford. Through bold initiatives in medical education and increased support for MD and PhD students, Dr. Minor is committed to inspiring and training future leaders. He also has increased student financial aid and expanded faculty leadership opportunities.
Among other accomplishments Dr. Minor has led the development and implementation of an innovative model for cancer research and patient care delivery at Stanford Medicine and has launched an initiative in biomedical data science to harness the power of big data and create a learning health care system.
Before Stanford, Dr. Minor was provost and senior vice president for academic affairs of The Johns Hopkins University. As provost, Dr. Minor launched many university-wide initiatives such as the Gateway Sciences Initiative to support pedagogical innovation, and the Doctor of Philosophy Board to promote excellence in PhD education. He worked with others around the university and health system to coordinate the Individualized Health Initiative, which aimed to use genetic information to transform health care.
Prior to his appointment as provost in 2009, Dr. Minor was the Andelot Professor and director (chair) of the Department of Otolaryngology-Head and Neck Surgery in the Johns Hopkins University School of Medicine and otolaryngologist-in-chief of The Johns Hopkins Hospital. During his six-year tenure, he expanded annual research funding by more than half and increased clinical activity by more than 30 percent, while strengthening teaching efforts and student training.
With more than 160 published articles and chapters, Dr. Minor is an expert in balance and inner ear disorders. Through neurophysiological investigations of eye movements and neuronal pathways, his work has identified adaptive mechanisms responsible for compensation to vestibular injury in a model system for studies of motor learning (the vestibulo-ocular reflex). The synergies between this basic research and clinical studies have led to improved methods for the diagnosis and treatment of balance disorders. In recognition of his work in refining a treatment for Ménière's disease, Dr. Minor received the Prosper Ménière Society's gold medal in 2010.
In the medical community, Dr. Minor is perhaps best known for his discovery of superior canal dehiscence syndrome, a debilitating disorder characterized by sound- or pressure-induced dizziness. In 1998, Dr. Minor and colleagues published a description of the clinical manifestations of the syndrome and related its cause to an opening (dehiscence) in the bone covering the superior canal. He subsequently developed a surgical procedure that corrects the problem and alleviates symptoms.
Dr. Minor received his bachelor's and medical degrees from Brown University. He trained at Duke University Medical Center and the University of Chicago Medical Center and completed a research fellowship at the University of Chicago and a clinical fellowship at The Otology Group and The EAR Foundation in Nashville, Tennessee.
In 2012, Dr. Minor was elected to the National Academy of Medicine.
Job Titles:
- Director, Medical Student Research & Scholarship
Sleep researcher Emmanuel Mignot identifies the defective gene that causes narcolepsy, a disabling sleep disorder affecting humans and animals.
Pathologist Eugene Butcher discovers a receptor that guides white blood cells into the peripheral lymph nodes.
Pathologist Gerald Crabtree develops techniques that allow scientists to toggle genes on and off in animal models.
Immunologist Hugh McDevitt discovers regulatory genes believed to control the body's reponses to foreign proteins, which suggests that people may have predictable susceptibility to certain diseases.
Pathologist Irving Weissman isolates a rare mouse cell, known as the hematopoetic stem cell, which gives rise to all the cells of the blood and immune systems.
Pathologist Irving Weissman identifies the stem cell that gives rise to bladder cancer, and also shows how the cell uses the "don't-eat-me" signal, a molecule known as CD47, to evade the body's defenses.
Pathologist Irving Weissman shows that a single antibody, which counters the effect of the CD47 molecule, shrinks a variety of human tumors transplanted into mice.
Job Titles:
- Peter Wood Lead the First Large Clinical Investigation That Shows Lowering Cholesterol Levels Prevents Heart Disease
John Farquhar and Peter Wood lead the first large clinical investigation that shows lowering cholesterol levels prevents heart disease.
Pathologist Marius Wernig turns mouse skin cells into cells that insulate neurons with the application of just three genes.
Immunologist Mark Davis characterizes the T-cell receptor, believed to regulate the body's response to infectious agents and cancerous diseases.
Mary Gohlke receives the world's first combined heart and lung transplant in a landmark operation led by surgeon Bruce Reitz.
Job Titles:
- Executive Assistant to Dean Lloyd Minor, MD, Office of the Dean, Chief of Staff
Job Titles:
- Peter Wood Lead the First Large Clinical Investigation That Shows Lowering Cholesterol Levels Prevents Heart Disease
Surgeon Roy Cohn leads the first human kidney transplant operation on the West Coast.
Radiologist Sanjiv Gambhir develops a new type of imaging system that can illuminate tumors in living subjects with a precision of nearly one-trillionth of a meter
Pediatrician Thomas Robinson finds that children who curtailed their television time gained significantly less body fat than those who didn't .
Researcher William Haskell shows that intensive lifestyle changes and prevention/treatment programs can reduce cardiac events and slow the progression of atherosclerosis in coronary arteries.
Researcher William S. Robinson isolates the genetic blueprint of a virus that causes hepatitis B and a common form of liver cancer.